Biobot Analytics was born at MIT

Our technology generates public health data that is naturally anonymized yielding unprecedented insight into the health of communities without collecting personal identifiable information.


How it works

Our technology integrates data science, chemistry and biology, and engineering.
This is how we do it:


We map the wastewater network to identify sampling locations that represent a city.


Our patent-pending automated sampling device collects samples representative of entire communities in easy-to-transport cartridges.


Samples are shipped to Biobot where scientists generate and analyze the extracted health data.

Public health

Collective rates are visualized in tables and maps in monthly reports.

Wastewater epidemiology was first pioneered in Israel, Europe, and Australia by various academic research collaborations.

The most well-known group is the European SCORE network, which is sponsored by the European Union. Developed in the United States at MIT, our methods build on top of this body of work allowing this technology to be commercialized for the first time. Our Co-founder and CEO developed this scientific innovation during her PhD work at MIT, and is one of a few experts in the United States in this scientific field.

Our system differs from the European work in three important ways:

Sub-city level geographic resolution

We collect our samples at manholes in the city and wastewater treatment facilities. This approach enables direct measurement of metabolites, viruses, and bacteria excreted by humans.

Near-real time

We're built to deliver results in a 3-day turnaround time. This is possible because we are dedicated full-time to delivering an efficient service through automation technology.

Chemical and biological capabilities

Our system can measure drug consumption, infectious disease outbreaks, antibiotic resistance, nutrition, and exposure to environmental contaminants in populations creating a holistic early warning system for public health crises.